All In Biotech

NDA 022068 · Novartis

Tasigna

Nilotinib Hydrochloride · Oral

NovelAccelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Oct 29, 2007

Approved uses

11

Original approval plus efficacy supplements

Registered trials

185

34 Phase 3, 10 recruiting

FAERS reports

29,425

21,731 serious, 5,641 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: QT PROLONGATION and SUDDEN DEATHS Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [see Warnings and Precautions (5.2)] . Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments [see Warnings and Precautions (5.2, 5.3, 5.7, 5.12)] . Sudden deaths have been reported in patients receiving Tasigna [see Warnings and Precautions (5.3)] . Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome [see Contraindications (4), Warnings and Precautions (5.2)] . Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [see Drug Interactions (7.1, 7.2)] . Avoid food 2 hours before and 1 hour after taking the dose [see Dosage and...

What it is approved for

From the label in effect Dec 16, 2025.

Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. ( 1.3 ) 1.1 Adult and Pediatric Patients With Newly Diagnosed Ph+ CML-CP Tasigna is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Adult Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. 1.3 Pediatric Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Tasigna is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.

Mechanism: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20 to 60 nM), PDGFR (69 nM), c-KIT...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TASIGNA · NILOTINIB HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • TASIGNA · NILOTINIB HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • TASIGNA · NILOTINIB HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nilotinib" as an intervention, any sponsor and status, largest first.

All 185 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,231
  • fatigue2,112
  • rash1,654
  • nausea1,546
  • headache1,494
  • dyspnoea1,395
  • pain1,344
  • diarrhoea1,222
  • drug ineffective1,210
  • malaise1,143
  • pruritus1,134
  • pyrexia1,134

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200710
2008254
2009340
2010450
2011955
20121,851
20131,549
20142,183
20152,111
20162,531
20171,984
20182,275
20192,686
20202,319
20212,175
20221,821
20231,545
20241,084
2025748
2026554

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tasigna (Nilotinib HCl)

2024 spending

$427M

Beneficiaries

3,054

26,420 claims

Per beneficiary

$139,804

$175.29 per unit

View as table
YearSpending
2020$339,500,199
2021$352,216,339
2022$375,995,128
2023$394,675,625
2024$426,961,765

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 259 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.